Glass Buildings
Clinical Trial Search Results
 

Offical Title

Safety and efficacy of intensive versus guideline antiplatelet therapy in high risk patients with recent ischaemic stroke or transient ischaemic attack: a randomised controlled trial

Brief Title

TARDIS

Start Date

18/03/2016

Primary Objective

To assess the safety of short-term administration (1 month) of intensive antiplatelet therapy (aspirin, dipyridamole and clopidogrel) versus current guideline therapy (dual aspirin and dipyridamole, or clopidogrel monotherapy) in patients with very recent ischaemic stroke or TIA

Category

Stroke

Offical Title

STI571 Prospective International RandomIsed Trial 2: A phase III, prospective randomised comparison of imatinib (STI571, Glivec/Gleevec) 400mg daily versus dasatinib (Sprycel) 100mg daily in patients with newly-diagnosed chronic phase chronic myeloid leukaemia.

Brief Title

SPIRIT 2

Start Date

09/12/2011

Primary Objective

To compare 5-year Event Free Survival (EFS) between the two treatment arms. The study is powered to demonstrate superiority of the dasatinib arm over the imatinib arm.

Category

Cancer

Offical Title

Working parties on leukaemia in adults and children trial in acute myeloid leukaemia or high risk myelodysplastic syndrome 17

Brief Title

AML 17

Start Date

31/12/2014

Primary Objective

To compare a total of three versus four courses of treatment in total, comparing one versus two courses of HD Ara-C in consolidation. In highrisk patients, to evaluate the value of allogeniec stem cell transplantation (SCT), whether standard allogeneic (allo-SCT) or non-myeloblative "mini" allogeneic (mini-SCT). To assess the clinical value of minimal residual disease monitoring (MRD) for patient overall survival

Category

Cancer

Offical Title

Myeloma X Relapse (Intensive)-a comparison of high versus low-dose alkylating agent consolidation regimens for relapsed myeloma

Brief Title

Myeloma X Relapse (Intensive)

Start Date

21/11/2012

Primary Objective

To determine the effect on freedom-from disease progression of a second autologous stem cell transplant (ASCT) compared with low-dose consolidation, following re-induction chemotherapy, in patients with relapsed myeloma previously treated with high-dose chemotherapy and ASCT

Category

Cancer

Offical Title

Does progresterone prophylaxis to prevent preterm labour improve outcome? � a randomised double blind placebo controlled trial

Brief Title

OPPTIMUM

Start Date

31/07/2015

Primary Objective

In women at high risk of preterm labour, does prophylactic vaginal natural progesterone, 200mg daily from 22 � 34 weeks gestation, compared to placebo: i.Improve obstetric outcome by lengthening pregnancy and thus reducing the incidence of preterm delivery (before 34 weeks gestation)? ii.Improve neonatal outcome by reducing a composite of death and major morbidity? iii.Lead to improved childhood cognitive and neurosensory outcomes at two years? iv.Represent cost effective management for women at high risk of preterm delivery?

Category

Obstetrics & Gynaecology

Offical Title

Immediate Delivery versus Expectant Management for women with Preterm Pre-labour Rupture of the Membranes close to Term. A Randomised Controlled Trial.

Brief Title

PPROMT

Start Date

01/07/2013

Primary Objective

Category

Obstetrics & Gynaecology

Offical Title

Insulin Resistance Intervention after Stroke

Brief Title

'IRIS'

Start Date

31/03/2014

Primary Objective

To determine if pioglitazone (a drug to treat insulin resistance), compared to placebo (a dummy medication), will reduce the overall risk for fatal or non-fatal stroke or fatal or non-fatal myocardial infarction (MI, commonly known as 'heart attack') among non-diabetic men and women aged 40 years or older with insulin resistance, who have experienced a recent stroke or transient ischaemic attack (a TIA, sometimes termed a 'mini-stroke). We hypothesize that, among non-diabetics with insulin resistance, pioglitazone will reduce the rate of occurrence of any main outcome (fatal or non-fatal stroke or MI) within four years from 27% to 22%.

Category

Stroke

Offical Title

MYELOMA XI - Randomised comparisons in myeloma patients of all ages of thalidomide, lenalidomide and bortezomib combinations and maintenance lenalidomide

Brief Title

MYELOMA XI

Start Date

08/03/2016

Primary Objective

To compare a thalidomide-containing regimen with two lenalidomide-containing regimens as induction treatment and to assess the value of lenalidomide maintenance for patients with newly diagnosed myeloma with respect to overall and progression free survival.

Category

Cancer

Offical Title

Fluoropyrimidine, Oxaliplatin & Targeted Receptor pre-Operative Therapy for colon cancer. A randomised trial assessing whether preoperative chemotherapy and/or an anti-EGFR monoclonal antibody improves outcome in high-risk operable colon cancer.

Brief Title

FOxTROT

Start Date

31/12/2016

Primary Objective

A high-quality, multi-centre randomised controlled trial to determine if giving the first 6 weeks of an optimum combination chemotherapy regimen prior to surgery, as opposed to 24 weeks post-surgery, can reduce the risk of recurrence in patients with high-risk operable colon cancer. The effect of the addition of the monoclonal antibody, EGFR, with demonstated results in later stage disease, will also be evaluated.

Category

Cancer

Offical Title

Trial of Optimal Therapy for Pseudomonas Eradication in Cystic Fibrosis

Brief Title

TORPEDO-CF

Start Date

05/10/2016

Primary Objective

This trial will assess whether fourteen days intravenous ceftazidime with tobramycin is superior to three months (12 weeks) oral ciprofloxacin. Both treatment regimes will be in conjunction with three months (12 weeks) nebulised colistin.

Category

Meds for Children

Offical Title

POETIC - Trial of Perioperative Endocrine Therapy - Individualising Care

Brief Title

POETIC

Start Date

11/01/2013

Primary Objective

To determine whether perioperative endocrine therapy with an aromatase inhibitor (AI) for two weeks before and after surgery (perioperative therapy) followed by standard adjuvant therapy improves outcome compared with standard therapy alone in postmenopausal women with hormone receptor positive breast cancer. To determine whether the proliferation marker Ki67 as measured by immunohistochemistry (IHC) in the excised cancer around 2 weeks after starting AI therapy will predict for relapse free survival (RFS) more effectively than the pre-treatment Ki67 value in the individual patient as suggested in a clinical pilot study. To determine whether molecular profiling 2 weeks after starting endocrine therapy predicts for long-term outcome in postmenopausal women with hormone receptor positive breast cancer better than in untreated patients.

Category

Cancer

Offical Title

Evaluation of the Methods and Management of Acute Coronary Events - 3: Investigating variation in hospital acute coronary syndrome outcomes

Brief Title

EMMACE-3

Start Date

22/02/2013

Primary Objective

Category

Cardiovascular

There are no results matching your search terms.